

Patient ID SA00141403	Patient Name ATLAS REPORT, ABNORMAL	Birth Date 1990-01-01	Gender F	Age 31
Order Number SA00141403	Client Order Number SA00141403	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 12 Jan 2021 09:00		

Sezary Diagnostic Flow Cytometry, B

Final Diagnosis

MCR

Peripheral blood, flow cytometric immunophenotyping:
Immunophenotypically distinct CD4-positive T-cell population suspicious for clonality is detected.

Comment:

In a proper clinical setting (erythroderma and/or generalized lymphadenopathy), this finding would support the diagnosis of Sezary syndrome. However, other T-cell lymphoproliferative disorders, such as peripheral blood involvement by mycosis fungoides, T-cell prolymphocytic leukemia, peripheral T-cell lymphoma or adult T-cell leukemia/lymphoma, cannot be ruled out from this analysis. In addition, reactive CD4-positive T-cells in Hodgkin lymphoma, other malignancies, and other non-neoplastic conditions can have a similar immunophenotype. Correlation with clinical and morphological findings is suggested. Performing molecular genetic analysis to assess for clonal T-cell receptor gene rearrangements might also be considered.

Reviewed by: SHANDA VOELTZ

Special Studies

MCR

WBC: 10.0 x 10(9)/L

%Lymphs (CBC/automated differential): 10%

#Lymphs (CBC/automated differential): 1.0 x 10(9)/L

Results:

Blasts: Not increased by CD45/side scatter and CD34.

B-cells: No monotypic; normal expression pattern of CD19, CD10, surface kappa and lambda.

T-cells/NK-cells: Distinct T-cell population.

Express: CD4, CD2, CD5, CD7 (partial). Do not express: CD26, CD8, CD16, CD3, TRBC1,. Estimated size: 62% gated lymphoid events; 26% total analyzed events

T-cell/NK-cell markers tested: Sezary panel: CD2, CD3, CD4, CD5, CD7, CD8, CD26, CD45 and TRBC1.

Flow cytometry analysis performed with antibodies to the following antigens: Triage panel: CD3, CD10, CD16, CD19, CD34, CD45 and kappa and lambda surface light chains. Sezary panel: CD2, CD3, CD4, CD5, CD7, CD8, CD26, CD45 and TRBC1.

Quality Assessment: Specimen received within validated guidelines.

Microscopic Description

1 MCR

A submitted Wright-Giemsa slide and a Wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined.

Sezary Diagnostic

MCR

Performed

Received: 12 Jan 2021 15:10

Reported: 15 Jan 2021 11:30

Laboratory Notes

- 1 This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292